First Light Asset Management LLC Has $9.01 Million Holdings in Dynavax Technologies (DVAX)

First Light Asset Management LLC raised its holdings in shares of Dynavax Technologies (NASDAQ:DVAX) by 9.2% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 453,634 shares of the biopharmaceutical company’s stock after acquiring an additional 38,061 shares during the quarter. Dynavax Technologies comprises approximately 2.0% of First Light Asset Management LLC’s portfolio, making the stock its 17th biggest holding. First Light Asset Management LLC owned approximately 0.73% of Dynavax Technologies worth $9,005,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. Commonwealth Equity Services LLC bought a new stake in Dynavax Technologies during the 1st quarter valued at $212,000. LPL Financial LLC bought a new stake in Dynavax Technologies during the 1st quarter valued at $283,000. Paloma Partners Management Co bought a new stake in Dynavax Technologies during the 4th quarter valued at $331,000. Lazard Asset Management LLC bought a new stake in Dynavax Technologies during the 4th quarter valued at $343,000. Finally, Teacher Retirement System of Texas bought a new stake in Dynavax Technologies during the 4th quarter valued at $379,000. 77.60% of the stock is currently owned by institutional investors and hedge funds.

In related news, insider Michael S. Ostrach sold 4,000 shares of the company’s stock in a transaction on Friday, June 8th. The shares were sold at an average price of $15.53, for a total value of $62,120.00. Following the completion of the transaction, the insider now directly owns 80,554 shares in the company, valued at $1,251,003.62. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 3.47% of the stock is currently owned by insiders.

DVAX has been the subject of a number of recent analyst reports. Royal Bank of Canada restated a “buy” rating and set a $25.00 price target on shares of Dynavax Technologies in a research report on Friday, March 9th. Cantor Fitzgerald restated a “buy” rating and set a $27.00 price target on shares of Dynavax Technologies in a research report on Tuesday, May 8th. ValuEngine upgraded shares of Dynavax Technologies from a “sell” rating to a “hold” rating in a research report on Tuesday, March 27th. BidaskClub upgraded shares of Dynavax Technologies from a “hold” rating to a “buy” rating in a research report on Monday, April 16th. Finally, Cowen restated a “buy” rating and set a $30.00 price target on shares of Dynavax Technologies in a research report on Wednesday, February 21st. Two equities research analysts have rated the stock with a sell rating and six have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $24.67.

Dynavax Technologies opened at $16.35 on Thursday, according to Marketbeat.com. The firm has a market cap of $983.93 million, a PE ratio of -9.45 and a beta of 0.81. The company has a quick ratio of 10.83, a current ratio of 10.85 and a debt-to-equity ratio of 0.60. Dynavax Technologies has a one year low of $7.40 and a one year high of $24.45.

Dynavax Technologies (NASDAQ:DVAX) last released its quarterly earnings results on Tuesday, May 8th. The biopharmaceutical company reported ($0.63) EPS for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.14). The firm had revenue of $0.17 million for the quarter, compared to analysts’ expectations of $0.82 million. Dynavax Technologies had a negative net margin of 31,635.17% and a negative return on equity of 60.61%. The firm’s revenue for the quarter was up 11.5% on a year-over-year basis. During the same quarter last year, the firm earned ($0.60) earnings per share. sell-side analysts forecast that Dynavax Technologies will post -2.27 EPS for the current fiscal year.

About Dynavax Technologies

Dynavax Technologies Corporation, a biopharmaceutical company, focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. The company's lead product candidates include HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of the virus in adults age 18 years and older; SD-101, a cancer immunotherapy that is in Phase 2 clinical studies; and DV281, an investigational TLR9 agonist for the treatment of non-small cell lung cancer.

Institutional Ownership by Quarter for Dynavax Technologies (NASDAQ:DVAX)

Receive News & Ratings for Dynavax Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply